Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave

Area of Science:

• Immunology
• Molecular Biology
• Cancer Research

Background:

• Programmed death-ligand 1 (PD-L1) is a key immune checkpoint molecule.
• Cancer cells utilize PD-L1 to suppress T cell activity via PD-1 engagement.
• PD-L1 expression impacts patient response to immune checkpoint inhibitor therapies.

Purpose of the Study:

• To review the molecular mechanisms regulating PD-L1 expression.
• To elucidate the role of posttranslational modifications (PTMs) in PD-L1 function.
• To discuss the implications of PTMs for anti-PD-1/PD-L1 therapies.

Main Methods:

• Literature review focusing on PTMs of PD-L1.
• Analysis of studies on PD-L1 regulation, trafficking, and immune response.
• Synthesis of information on PTMs' impact on immunotherapy.

Main Results:

• PTMs, including phosphorylation, glycosylation, ubiquitination, and acetylation, critically control PD-L1 stability and localization.
• Balanced regulation of PD-L1 by PTMs is essential for its function.
• PTMs influence the effectiveness of anti-PD-1/PD-L1 cancer therapies.

Conclusions:

• Posttranslational modifications are central regulators of PD-L1.
• Targeting PTMs offers a potential strategy to enhance cancer immunotherapy efficacy.
• Further research into PD-L1 PTMs can optimize clinical outcomes.